Bioluminescent imaging of hepatocellular carcinoma in live mice

Biotechnol Lett. 2007 Nov;29(11):1665-70. doi: 10.1007/s10529-007-9452-0. Epub 2007 Jul 4.

Abstract

A non-invasive orthotopic hepatocellular carcinoma (HCC) model was created with human HCC cells (HepG-Luc) constitutively expressing luciferase (Luc) in nude mice. Development of tumor growth and response to anti-tumor therapy combined with 5-fluorouracil and cisplatin was monitored by whole-body bioluminescent imaging (BLI). Luciferase activity in the tumor, determined by BLI, correlated with the tumor volume and weight. The anti-tumor therapy proved effective by BLI monitoring. In conclusion, BLI by luciferase provides a non-invasive method of monitoring tumor activities that can prove useful for therapeutic intervention studies.

MeSH terms

  • Animals
  • Antimetabolites, Antineoplastic / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / enzymology*
  • Diagnostic Imaging / methods
  • Disease Models, Animal
  • Endpoint Determination
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Liver Neoplasms, Experimental / drug therapy
  • Liver Neoplasms, Experimental / enzymology*
  • Luciferases / analysis*
  • Luciferases / metabolism
  • Mice
  • Mice, Inbred BALB C
  • Treatment Outcome
  • Xenograft Model Antitumor Assays

Substances

  • Antimetabolites, Antineoplastic
  • Luciferases
  • Fluorouracil